---
document_datetime: 2025-11-23 08:01:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-teva.html
document_name: pioglitazone-teva.html
version: success
processing_time: 0.1223869
conversion_datetime: 2025-12-28 08:57:33.912359
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pioglitazone Teva

[RSS](/en/individual-human-medicine.xml/65748)

##### Withdrawn

This medicine's authorisation has been withdrawn

pioglitazone

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 31 March 2023, the European Commission withdrew the marketing authorisation for Pioglitazone Teva (pioglitazone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Pioglitazone Teva was granted marketing authorisation in the EU on 26 March 2012 for the treatment of type 2 diabetes mellitus. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity on 17 February 2017.

Pioglitazone Teva is a generic medicine of Actos, which is authorised and marketed in the EU to treat type 2 diabetes mellitus.

The European Public Assessment Report (EPAR) for Pioglitazone Teva is updated to indicate that the marketing authorisation is no longer valid.

Pioglitazone Teva : EPAR - Summary for the public

Reference Number: EMA/222728/2012

English (EN) (636.05 KB - PDF)

**First published:** 10/04/2012

**Last updated:** 04/05/2023

[View](/en/documents/overview/pioglitazone-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-606)

български (BG) (806.53 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/bg/documents/overview/pioglitazone-teva-epar-summary-public_bg.pdf)

español (ES) (698.1 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/es/documents/overview/pioglitazone-teva-epar-summary-public_es.pdf)

čeština (CS) (775.18 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/cs/documents/overview/pioglitazone-teva-epar-summary-public_cs.pdf)

dansk (DA) (638.91 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/da/documents/overview/pioglitazone-teva-epar-summary-public_da.pdf)

Deutsch (DE) (698.57 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/de/documents/overview/pioglitazone-teva-epar-summary-public_de.pdf)

eesti keel (ET) (698.03 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/et/documents/overview/pioglitazone-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (813.13 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/el/documents/overview/pioglitazone-teva-epar-summary-public_el.pdf)

français (FR) (700.69 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/fr/documents/overview/pioglitazone-teva-epar-summary-public_fr.pdf)

italiano (IT) (714.74 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/it/documents/overview/pioglitazone-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (748.61 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/lv/documents/overview/pioglitazone-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (663.55 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/lt/documents/overview/pioglitazone-teva-epar-summary-public_lt.pdf)

magyar (HU) (707.11 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/hu/documents/overview/pioglitazone-teva-epar-summary-public_hu.pdf)

Malti (MT) (773.35 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/mt/documents/overview/pioglitazone-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (698.64 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/nl/documents/overview/pioglitazone-teva-epar-summary-public_nl.pdf)

polski (PL) (774.44 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/pl/documents/overview/pioglitazone-teva-epar-summary-public_pl.pdf)

português (PT) (696.95 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/pt/documents/overview/pioglitazone-teva-epar-summary-public_pt.pdf)

română (RO) (664.63 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/ro/documents/overview/pioglitazone-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (770.33 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/sk/documents/overview/pioglitazone-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (767.4 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/sl/documents/overview/pioglitazone-teva-epar-summary-public_sl.pdf)

Suomi (FI) (698.83 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/fi/documents/overview/pioglitazone-teva-epar-summary-public_fi.pdf)

svenska (SV) (696.94 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/sv/documents/overview/pioglitazone-teva-epar-summary-public_sv.pdf)

Pioglitazone Teva : EPAR - Risk-management-plan summary

English (EN) (624.32 KB - PDF)

**First published:** 28/07/2020

**Last updated:** 04/05/2023

[View](/en/documents/rmp-summary/pioglitazone-teva-epar-risk-management-plan-summary_en.pdf)

## Product information

Pioglitazone Teva : EPAR - Product Information

English (EN) (1.11 MB - PDF)

**First published:** 28/07/2020

**Last updated:** 04/05/2023

[View](/en/documents/product-information/pioglitazone-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-297)

български (BG) (2.02 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/bg/documents/product-information/pioglitazone-teva-epar-product-information_bg.pdf)

español (ES) (1.1 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/es/documents/product-information/pioglitazone-teva-epar-product-information_es.pdf)

čeština (CS) (1.78 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/cs/documents/product-information/pioglitazone-teva-epar-product-information_cs.pdf)

dansk (DA) (1.11 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/da/documents/product-information/pioglitazone-teva-epar-product-information_da.pdf)

Deutsch (DE) (1.18 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/de/documents/product-information/pioglitazone-teva-epar-product-information_de.pdf)

eesti keel (ET) (1.11 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/et/documents/product-information/pioglitazone-teva-epar-product-information_et.pdf)

ελληνικά (EL) (2.12 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/el/documents/product-information/pioglitazone-teva-epar-product-information_el.pdf)

français (FR) (1.14 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/fr/documents/product-information/pioglitazone-teva-epar-product-information_fr.pdf)

hrvatski (HR) (1.16 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/hr/documents/product-information/pioglitazone-teva-epar-product-information_hr.pdf)

íslenska (IS) (1.11 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/is/documents/product-information/pioglitazone-teva-epar-product-information_is.pdf)

italiano (IT) (1.13 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/it/documents/product-information/pioglitazone-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.79 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/lv/documents/product-information/pioglitazone-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.15 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/lt/documents/product-information/pioglitazone-teva-epar-product-information_lt.pdf)

magyar (HU) (1.74 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/hu/documents/product-information/pioglitazone-teva-epar-product-information_hu.pdf)

Malti (MT) (1.85 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/mt/documents/product-information/pioglitazone-teva-epar-product-information_mt.pdf)

Nederlands (NL) (1.12 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/nl/documents/product-information/pioglitazone-teva-epar-product-information_nl.pdf)

norsk (NO) (1.13 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/no/documents/product-information/pioglitazone-teva-epar-product-information_no.pdf)

polski (PL) (1.82 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/pl/documents/product-information/pioglitazone-teva-epar-product-information_pl.pdf)

português (PT) (1.13 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/pt/documents/product-information/pioglitazone-teva-epar-product-information_pt.pdf)

română (RO) (1.22 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/ro/documents/product-information/pioglitazone-teva-epar-product-information_ro.pdf)

slovenčina (SK) (1.79 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/sk/documents/product-information/pioglitazone-teva-epar-product-information_sk.pdf)

slovenščina (SL) (1.73 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/sl/documents/product-information/pioglitazone-teva-epar-product-information_sl.pdf)

Suomi (FI) (1.13 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/fi/documents/product-information/pioglitazone-teva-epar-product-information_fi.pdf)

svenska (SV) (1.12 MB - PDF)

**First published:**

28/07/2020

**Last updated:**

04/05/2023

[View](/sv/documents/product-information/pioglitazone-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0025 04/11/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pioglitazone Teva : EPAR - All Authorised presentations

English (EN) (594.79 KB - PDF)

**First published:** 10/04/2012

**Last updated:** 04/05/2023

[View](/en/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-409)

български (BG) (647.96 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/bg/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (597.6 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/es/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (623.96 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/cs/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (598.33 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/da/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (596.47 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/de/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (600.83 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/et/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (651.29 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/el/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (594.42 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/fr/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (593.28 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/is/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (595.34 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/it/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (639.69 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/lv/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (625.13 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/lt/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (640.79 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/hu/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (638.55 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/mt/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (599.85 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/nl/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (596.61 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/no/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (623.95 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/pl/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (595.51 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/pt/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (623.32 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/ro/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (638.75 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/sk/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (610.12 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/sl/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (595.16 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/fi/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (595.08 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/sv/documents/all-authorised-presentations/pioglitazone-teva-epar-all-authorised-presentations_sv.pdf)

Pioglitazone Teva : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (602.92 KB - PDF)

**First published:** 10/04/2012

**Last updated:** 04/05/2023

[View](/en/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (22)](#file-language-dropdown-792)

български (BG) (702.36 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/bg/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (603.16 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/es/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (701.28 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/cs/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (597.36 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/da/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (604.17 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/de/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (602.64 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/et/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (700.03 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/el/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (603.69 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/fr/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (603.62 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/is/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (602.8 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/it/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (704.74 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/lv/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (670.52 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/lt/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (667.73 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/hu/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (702.84 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/mt/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

norsk (NO) (603.22 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/no/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (702.45 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/pl/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (598.07 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/pt/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (667.78 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/ro/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (693.87 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/sk/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (692.99 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/sl/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (597.87 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/fi/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (603.53 KB - PDF)

**First published:**

10/04/2012

**Last updated:**

04/05/2023

[View](/sv/documents/conditions-member-states/pioglitazone-teva-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Pioglitazone Teva Active substance pioglitazone hydrochloride International non-proprietary name (INN) or common name pioglitazone Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BG03

### Pharmacotherapeutic group

Alimentary tract and metabolism

### Therapeutic indication

Pioglitazone is indicated in the treatment of type 2 diabetes mellitus:

- as monotherapy
- as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea
- as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

## Authorisation details

EMA product number EMEA/H/C/002297

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5 2031GA Haarlem The Netherlands

Opinion adopted 19/01/2012 Marketing authorisation issued 26/03/2012 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pioglitazone Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (728.68 KB - PDF)

**First published:** 14/07/2014

**Last updated:** 04/05/2023

[View](/en/documents/procedural-steps-after/pioglitazone-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pioglitazone Teva : EPAR - Public assessment report

Adopted

Reference Number: EMEA/CHMP/844031/2011

English (EN) (953.89 KB - PDF)

**First published:** 10/04/2012

**Last updated:** 04/05/2023

[View](/en/documents/assessment-report/pioglitazone-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pioglitazone Teva

Adopted

Reference Number: EMA/CHMP/756122/2011

English (EN) (646.4 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 04/05/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-teva_en.pdf)

**This page was last updated on** 04/05/2023

## Share this page

[Back to top](#main-content)